Skip to content

Study of the preventive effect of ingestion of foods containing natural product-derived ingredients on arteriosclerosis

Study of the preventive effect of ingestion of foods containing natural product-derived ingredients on arteriosclerosis -Placebo-controlled, randomized, double-blind, parallel-group comparative study- - Preventive effect of ingestion of test food on arteriosclerosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000048377
Enrollment
40
Registered
2022-07-15
Start date
2022-07-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

Daily ingestion 1 pack of food containing natural product-derived ingredients (EsV3) for 14 weeks. Daily ingestion 1 pack of placebo food for 14 weeks.

Sponsors

HYDROX Inc.
Lead Sponsor
NANOHANA CLINIC SQL INC.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Subjects who have received adequate explanation and understand the purpose and content of this study, volunteered freely, and are able to give their own written informed consent. (2)Healthy males and females from 20 to 65 years of age

Exclusion criteria

Exclusion criteria: (1)Subjects with allergies (drugs and test food-related foods) (2)Females who are pregnant, lactating, or willing to become pregnant during the study period (3)Subjects being treated for the following diseases Malignant tumore, renal failure, heart failure, myocardial infarction, cerebral infarction, immunodeficiency, collagen disease (4)Subjects with pacemakers or implantable cardioverter defibrillators (5)Smokers (average 21 cigarettes per day or more), regular users of alcohol (average daily net alcohol of 60g or more), or those with extremely irregular lifestyle habits. (6)Subjects taking prescription drugs that affect the study (7)Subjects who have participated in other clinical trials for 28 days before the date of informed consent or who are scheduled to participate during the study period. (8)Subjects who were deemed inappropriate for inclusion in the study by the investigator

Design outcomes

Primary

MeasureTime frame
Urinary UrotensinII levels Fingertip capillary clinical images Blood pressure and pulse

Secondary

MeasureTime frame
Various questionnaires, Blood oxygen saturation concentration, Comparison of the results of the previous year's and post-trial checkups, Optional persistent blood glucose measurement

Countries

Japan

Contacts

Public ContactAyako Nakata

SQL INC. CRC

nakata@sql-i.com090-1706-1329

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026